Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome)

International Archives of Allergy and Immunology

Volumn 136, Issue 3, 2005, Pages 205-216

  Paquet, Philippe ^a,b   Piérard, Gérald E ^a   Quatresooz, Pascale ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU SART TILMAN   (Belgium)

Author keywords

Corticosteroid; Cyclosporin A; Drug reaction; Immunoglobulin; Lyell's syndrome

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; CARBAMAZEPINE; CETRIMIDE; CHLORHEXIDINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOGLOBULIN; ISOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; OXYPHENBUTAZONE; PENTOXIFYLLINE; PHENOBARBITAL; PHENYLBUTAZONE; PHENYTOIN; PIROXICAM; POVIDONE IODINE; PREDNISOLONE; PREDNISONE; SILVER NITRATE; SULFONAMIDE; ULINASTATIN; UNINDEXED DRUG;

ANTICOAGULATION; BACTERIAL INFECTION; CLINICAL TRIAL; DEBRIDEMENT; DRUG EFFICACY; HISTOPATHOLOGY; HOSPITAL INFECTION; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOHISTOCHEMISTRY; INFECTION COMPLICATION; NEPHROTOXICITY; NONHUMAN; NUTRITIONAL SUPPORT; PATHOGENESIS; PATIENT MONITORING; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SEPSIS; SIDE EFFECT; TOXIC EPIDERMAL NECROLYSIS; APOPTOSIS; COMPARATIVE STUDY; DRUG EFFECT; KERATINOCYTE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

APOPTOSIS; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; KERATINOCYTES;

EID: 16444376419     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083947     Document Type: Review

References (114)

1. Fritsch PO, Sidoroff A: Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000;1:349-360.
2. Roujeau JC: The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: A clinical classification. J Invest Dermatol 1994;102:28S-30S.
3. Roujeau JC: Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997;24:726-729.
4. Paquet P, Piérard GE: Erythema multiforme and toxic epidermal necrolysis. A comparative study. Am J Dermatopathol 1997;19:127-132.
5. Guillaume JC, Roujeau JC, Revuz J, Penso D, Touraine R: The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol 1987;123:1166-1170.
6. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern R, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F: Medication use and the risk of Stevens-Johnson or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-1607.
7. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W: Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986;105:179-184.
8. Pirmohamed M, Graham A, Roberts P, Smith D, Chadwick D, Breckenridge AM, Park BK: Carbamazepine-hypersensitivity: Assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br J Clin Pharmacol 1991;32:741-749.
9. Wolkenstein P, Charue D, Laurent P, Revuz J, Roujeau JC, Bagot M: Metabolic predisposition to cutaneous adverse drug reactions. Arch Dermatol 1995;131:544-551.
10. Wolkenstein P, Tan C, Lecoeur S, Wechsler J, Garcia-Martin N, Charue D, Bagot M, Beaune P: Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin. Chem Biol Interact 1998;113:39-50.
11. Reilly TP, Lash L, Doll MA, Hein DW, Woster PM, Svensson CK: A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest Dermatol 2000;114:1164-1173.
12. Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC, Beaune P, Bagot M: A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995;5:255-258.
13. Dietrich A, Kowakubo Y, Rzany B, Mockenhaupt M, Simon JC, Schöpf E: Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp Dermatol 1995;4:313-316.
14. Saiag P, Cauns E, Chosidow O, Revuz J, Roujeau JC: Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992;26:567-574.
15. Lee BL, Wong D, Benowitz N, Sullam PM: Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993;53:529-535.
16. Baron JM, Merk HF: Drug metabolism in the skin. Curr Opin Allergy Clin Immunol 2001;1:287-291.
17. Paquet P, Nikkels A, Arrese JE, Vanderkelen A, Piérard GE: Macrophages and tumor necrosis factor-alpha in toxic epidermal necrolysis. Arch Dermatol 1994;130:605-608.
18. Paquet P, Piérard GE: Soluble fractions of tumor necrosis factor-α, interleukin 6 and of their receptors in toxic epidermal necrolysis. A comparison with second-degree burns. Int J Mol Med 1998;1:459-462.
19. Correia O, Delgado L, Leal Barbosa I, Campilho F, Fleming-Torrinha J: Increased interleukin 10, tumor necrosis factor α and interleukin 6 level in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol 2002;47:58-62.
20. Paquet P, Piérard GE: Epidermal calprotectin in drug-induced toxic epidermal necrolysis. J Cutan Pathol 1999;26:301-305
21. Paquet P, Piérard GE: Keratinocyte injury in drug-induced toxic epidermal necrolysis: Simultaneous but distinct topographic expression of CD95R and calprotectin. Int J Mol Med 2002;10:145-147.
22. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-493.
23. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H: Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003;162:1515-1520.
24. De Maria R, Teste R: Fas-FasL interactions: A common pathogenic mechanism in organ-specific autoimmunity. Immunol Today 1998;19:121-125.
25. Arnold R, Seifert M, Asadullah K, Volk HD: Cross-talk between keratinocytes and T lymphocytes via Fas/Fas ligand interaction: Modulation by cytokines. J Immunol 1999;162:7140-7147.
26. Correia O, Delgado L, Ramos JP, Resende C, Fleming-Torrinha JA: Cutaneous T cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993;129:466-468.
27. Correia O, Delgado L, Barbosa IL, Domingues JC, Azevado R, Vaz CP, Pimentel P: CD8+ lymphocytes in the blister fluid of severe acute cutaneous graft-versus-host disease: Further similarities with toxic epidermal necrolysis. Dermatology 2001;203:212-216.
28. Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A, Roujeau JC: Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 2000;119:225-230.
29. Paquet P, Arrese JE, Beguin Y, Piérard GE: Clinicopathological differential diagnosis of drug-induced toxic epidermal necrolysis (Lyell's syndrome) and acute graft-versus-host reaction; in Cerio R (ed): Current Topics in Pathology, vol 94: Dermatopathology. Berlin, Springer, 2001, pp 65-78.
30. Paquet P, Paquet F, Al Saleh W, Reper P, Vanderkelen A, Piérard GE: Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol 2000;22:413-417.
31. Hermanns-Lê T, Paquet P, Piérard-Franchimont C, Arrese JE, Piérard GE: Regulatory function of factor XIIIa-positive dendrocytes in incipient toxic epidermal necrolysis and graft-versus-host reaction. A hypothesis. Dermatology 1999;198:184-186.
32. Kondo S, Kooshesh F, Sauder D: Penetration of keratinocyte-derived cytokines into basement membrane. J Cell Physiol 1997;171:190-195.
33. Paquet P, Quatresooz P, Piérard GE: Factor XIIIa-positive dendrocytes in drug-induced toxic epidermal necrolysis (Lyell's syndrome). Paradoxical activation in the skin and rarefaction in lymph nodes. Dermatology 2003;206:374-378.
34. Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, Roujeau JC: Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996;134:710-714.
35. Wyllie AH: Apoptosis: An overview. Br Med Bull 1997;53:451-465.
36. Fulda S, Sieverb H, Frisen C, Herr I, Debatin KM: The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997;57:3823-3829.
37. Paquet P, Piérard GE: Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatology 1999;198:198-202.
38. Lerner LH, Qureshi AA, Reddy BV, Lerner EA: Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome. J Invest Dermatol 2000;114:196-199.
39. Lange RW, Hayden PJ, Chignell CF, Luster MI: Anthralin stimulates keratinocyte-derived pro-inflammatory cytokines via generation of reactive oxygen species. Inflamm Res 1998;47:174-181.
40. Ettore A, Andreassi M, Anselmi C, Neri P, Andreassi L, Di Stefano A: Involvement of oxidative stress in apoptosis induced by a mixture of isothiazolinones in normal human keratinocytes. J Invest Dermatol 2003;121:328-336.
41. Paquet P, Piérard GE: Differential pathomechanisms of epidermal necrolytic blistering diseases. Int J Mol Med 2002;10:695-699.
42. Garcia-Doval I, Le Cleach L, Bocquet H, Otero XL, Roujeau JC: Toxic epidermal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000;136:323-327.
43. Paquet P, Jacob E, Damas P, Piérard GE: Recurrent fatal drug-induced toxic epidermal necrolysis (Lyell's syndrome) following putative β-lactam cross-reactivity: Case report and scrutiny of antibiotic imputability. Crit Care Med 2002;30:2580-2583.
44. Herndon D: Toxic epidermal necrolysis: A systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J Am Coll Surg 1995;180:340-342.
45. Kelemen JJ, Cioffi W, McManus W, Mason A, Pruitt B: Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995;180:273-278.
46. Revuz J, Roujeau JC, Guillaume JC, Penso D, Touraine R: Treatment of toxic epidermal necrolysis. Arch Dermatol 1987;123:1156-1158.
47. Spies M, Sanford AP, Aili Low JF, Wolf S, Herndon D: Treatment of extensive toxic epidermal necrolysis in children. Pediatrics 2001;108:1162-1168.
48. Ghislain PD, Roujeau JC: Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002;8:5-15.
49. Arevalo JM, Lorente JA: Skin coverage with Biobrane biomaterial for the treatment of patients with toxic epidermal necrolysis. J Burn Care Rehabil 1999;20:406-410.
50. Trautmann A, Akdis M, Schmid-Grendelmeier P, Disch R, Brocker EB, Blaser K: Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol 2001;108:839-846.
51. Kull FC: Reduction in tumor necrosis factor receptor affinity and cytotoxicity by glucocorticoids. Biochem Biophys Res Commun 1988;153:402-409.
52. Beyaert R, Suffys P, Van Roy F, Fiers W: Inhibition by glucocorticoids of tumor necrosis factor-mediated cytotoxicity. Evidence against lipocortin involvement. FEBS Lett 1990;262:93-96.
53. Chambaut-Guerin AM, Thanopoulos P: Regulation by dexamethasone and 1,25-dihydroxyvitamin D3 of the 75 kD type A tumor necrosis factor receptor surface expression and mRNA level in human U937 cells. Eur Cytokine Netw 1991;2:355-358.
54. Kurtz RM, Elner VM, Bian ZM, Strieter RM, Kunkel SC, Elner SG: Dexamethasone and cyclosporine A modulation of human retinal pigment epithelial cell monocyte chemotactic protein-1 and interleukin-8. Invest Ophthalmol Vis Sci 1997;38:436-445.
55. Wutrich RP, Sekar P: Effect of dexamethasone, 6-mercaptopurine and cyclosporine A on intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression. Biochem Pharmacol 1993;46:1349-1353.
56. Robert C, Kupper TS: Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999;341:1817-1828.
57. Bemelmans M, Abramowicz D, Gouma P, Goldman M, Buurman W: In vivo T cell activation by anti-CD3 monoclonal antibody induces soluble TNF-receptor release in mice. Effects of pentoxifylline, methylprednisolone, anti-TNF and anti-IFN-γ antibodies. J Immunol 1994;153:499-506.
58. Bjornberg A: Fifteen cases of toxic epidermal necrolysis. Acta Dermatol 1973;15:149-152.
59. Anhalt G, Snelling CF: Toxic epidermal necrolysis. Plast Reconstr Surg 1978;61:905-910.
60. Simons HW: Acute life threatening dermatologic disorders. Med Clin North Am 1981;65:227-243.
61. Finlay AY, Richards J, Holt PJ: Intensive therapy unit management of toxic epidermal necrolysis: Practical aspects. Clin Exp Dermatol 1982;7:55-60.
62. Criton S, Devi K, Sridevi PK, Asokan PV: Toxic epidermal necrolysis - A retrospective study. Int J Dermatol 1997;36:923-925.
63. Stables GI, Lever RS: Toxic epidermal necrolysis and systemic corticosteroids. Br J Dermatol 1993;128:357.
64. Tegelberg-Stassen MJAM, Van Vloten WA, Baart de la Faille H: Management of nonstaphylococcal toxic epidermal necrolysis: Follow-up study of 16 case histories. Dermatologica 1990;180:124-129.
65. Rzany B, Schmitt H, Schöpf E: Toxic epidermal necrolysis in patients receiving glucocorticoids. Acta Derm Venereol 1991;71:171-172.
66. Guibal F, Bastuji-Garin S, Chosidow O, Saiag P, Revuz J, Roujeau JC: Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 1995;131:669-672.
67. Halebian P, Corder V, Madden M, Finkelstein JL, Shires GT: Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986;204:503-512.
68. Prendiville JS, Hebert A, Greenwald MJ, Esterly N: Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1989;115:881-887.
69. Jones WG, Halebran P, Madden M, Finkelstein J, Goodwin C: Drug-induced toxic epidermal necrolysis in children. J Pediatr Surg 1989;70:167-170.
70. Ward DJ, Krzeminska EC, Tanner NSB: Treatment of toxic epidermal necrolysis and a review of six cases. Burns 1990;16:97-104.
71. Khoo AKM, Foo CL: Toxic epidermal necrolysis in a burns centre: A 6-year review. Burns 1996;22:275-278.
72. Engelhardt SL, Schurr MJ, Helgerson RB: Toxic epidermal necrolysis: An analysis of referral patterns and steroid usage. J Burn Care Rehabil 1997;18:520-524.
73. Sheridan RL, Weber JM, Schulz JT, Ryan CM, Low HM, Tompkins RG: Management of severe toxic epidermal necrolysis in children. J Burn Care Rehabil 1999;20:497-500.
74. Schulz JT, Sheridan RL, Ryan CM, MacKool B, Tompkins RG: A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000;21:199-204.
75. Phan TG, Wang R, Crotty T, Adelstein S: Toxic epidermal necrolysis treated with intravenous gammaglobulin. Austr J Dermatol 1999;40:153-157.
76. Magina S, Lisboa C, Goncalves E, Conceicao P, Leal U, Mesquita-Guimaraes J: A case of toxic epidermal necrolysis treated with intravenous immunoglobulin. Br J Dermatol 2000;142:177-178.
77. Stella M, Cassano P, Bollero D, Clemente A, Giorio G: Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: Our experience. Dermatology 2001;203:45-49.
78. Paquet P, Jacob E, Damas P, Piérard GE: Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins. Burns 2001;27: 652-655.
79. Tristani-Firouzi P, Ptersen M, Saffle JR, Morris SE, Zone JJ: Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002;47: 548-552.
80. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE; TEN-IVIG Study Group: Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins. Arch Dermatol 2003;139:26-32.
81. Bachot N, Revuz J, Roujeau JC: Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2003;139:33-36.
82. Trent JT, Kirsner RS, Romanelli P, Kerdel FA: Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN. Arch Dermatol 2003;139:39-43.
83. Paquet P, Jacob E, Damas P, Pirson J, Piérard GE: Treatment of drug-induced toxic epidermal necrolysis by intravenous human immunoglobulins or cyclosporin A. A pilot study using analytical quantification of the inflammatory cell infiltrate and CD95R expression. Arch Dermatol Res, in press.
84. Renfro L, Grant-Kels J, Damman LA: Drug-induced toxic epidermal necrolysis treated with cyclosporin. Int J Dermatol 1989;28:441-444.
85. Zaki I, Patl S, Reed R, Dalziel KL: Toxic epidermal necrolysis associated with severe hypocalcaemia, and treated with cyclosporin. Br J Dermatol 1995;133:337-338.
86. Sullivan JR, Watson A: Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: A discussion of pathogenesis and immunosuppressive management. Australas J Dermatol 1996;37:208-212.
87. Jarrett P, Rademaker M, Havill J, Pullon H: Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony simulating factor. Clin Exp Dermatol 1997;22:146-147.
88. Murdoch SR, Fenton DA: Toxic epidermal necrolysis and cyclosporin. Clin Exp Dermatol 1997;22:250-256.
89. Szepietowki J, Wasik F, Szybejko-Machay G, May J: Toxic epidermal necrolysis successfully treated with cyclosporin. Report of three cases. J Eur Acad Dermatol Venereol 1997;9:169-172.
90. Arevalo J, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J: Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000;48:473-478.
91. Paquet P, Arrese Estrada J, Piérard GE: Oral cyclosporin and alopecia areata. Dermatology 1992;105:314-315.
92. Redondo P, Subira ML: N-acetylcysteine inhibits production of tumor necrosis factor-α and interleukin-1β. Arch Intern Med 1996;156:1238-1241.
93. Redondo P, De Felipe I, De la Pena A, Azamendra JM, Vanaclocha U: Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine. Br J Dermatol 1997;136:633-634.
94. Velez A, Moreno JC: Toxic epidermal necrolysis treated with N-acetylcysteine. J Am Acad Dermatol 2002;46:469-470.
95. Han J, Thompson P, Beutler B: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990;172:391-394.
96. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP 3rd, Larrick J, Kunkel SL: Cellular and molecular regulation of tumor necrosis factor-α production by pentoxifylline. Biochem Biophys Res Commun 1988;155:1230-1236.
97. Reed WR, DeGowin RL: Suppressive effects of pentoxifylline on natural killer cell activity. J Lab Clin Med 1992;119:763-771.
98. Redondo P, Ruiz de Erenchun F, Iglesias ME, Mondero P, Quintanilla E: Toxic epidermal necrolysis treatment with pentoxifylline. Br J Dermatol 1994;130:688-689.
99. Sanclemente G, De la Roche C, Escobar C, Falabella R: Pentoxifylline in toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol 1998;38:873-874.
100. Heng MCY, Allen SG: Efficacy of cylophosphamide in toxic epidermal necrolysis. J Am Acad Dermatol 1991;25:778-786.
101. Frangogiannis NG, Boridy F, Mazhar M, Mathews R, Gangopadhyay S, Cate T: Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J 1996;89:1001-1003.
102. Calderon P, Anzilotti M, Phelps R: Thalidomide in dermatology. New indications for an old drug. Int J Dermatol 1997;36:881-887.
103. Klausner JD, Freedman VH, Kaplan G: Thalidomide as an anti-TNF-α inhibitor: Implications for clinical use. Clin Immunol Immunopathol 1996;81:219-223.
104. Wolkenstein P, Latarjet P, Roujeau JC: Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-1589.
105. Miyachi H, Azuma A, Hioki E, Kobayashi Y, Iwasaki S, Hashimoto Y: Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-α production. Biochem Biophys Res Commun 1996;224:426-430.
106. Pizarro A, Garcia-Tobaruela A, Herranz P, Pinilla J: Thalidomide as an inhibitor of tumor necrosis factor-α production: Word of caution. Int J Dermatol 1999;38:76-77.
107. Klausner JD, Kaplan G, Haslett P: Thalidomide in toxic epidermal necrolysis. Lancet 1999;353:324.
108. Fischer M, Fiedler E, Marsch WC, Wohlrab J: Antitumour necrosis factor-α antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002;146:707-708.
109. Goulden V, Goodfield MJD: Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis. Br J Dermatol 1996;135:305-306.
110. Inamo Y, Okubo T, Wada M, Fuchigami S, Hashimoto K, Fuchigami T, Takahashi S, Sawada S, Harada K: Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients. Int Arch Allergy Immunol 2002;127:89-94.
111. Chaidemenos G, Chrysomallis F, Sombolos K, Mourellou O, Ioannides D, Papakonstantinou M: Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 1997;36:218-221.
112. Egan CA, Grant WJ, Morris SE, Saffle JR, Zone JJ: Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999;40:458-461.
113. Furubacke A, Berlin G, Anderson C, Sjoberg F: Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? Intensive Care Med 1999;25:1307-1310.
114. Paquet P, Nusgens B, Piérard GE, Lapière ChM: Gelatinases in drug-induced toxic epidermal necrolysis. Eur J Clin Invest 1998;28:528-532.